Remove Drug Pricing Remove Insurance Coverage and Processing Remove Packaging
article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHC 2024 Policy Priorities

Putting Patients First Blog

In response, a debt ceiling package was signed without Medicaid work requirements, symbolizing the power of patient advocates’ voices. Other areas where the NHC continued to make strides in its advocacy included telehealth expansion, health care transparency, and pharmacy benefit manager reforms.

article thumbnail

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

Go deeper with GlobalData Reports United States of America (USA) Drug Pricing and Reimbursement Lands. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports United States of America (USA) Drug Pricing and Reimbursement Lands.